TD Cowen raised the firm’s price target on Exact Sciences (EXAS) to $90 from $74 and keeps a Buy rating on the shares. The firm said Q3 results were solid with the strongest quarterly Cologuard volume growth (+23% Y/Y) and most sales upside (5% greater than cons.) in nearly 3 yrs.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences price target raised to $85 from $75 at BTIG
- Exact Sciences price target raised to $80 from $67 at Stifel
- Exact Sciences: Strong Growth Potential and Strategic Initiatives Justify Buy Rating
- Exact Sciences price target raised to $77 from $65 at Barclays
- Exact Sciences: Strong Q3 Performance and Promising Outlook Drive Buy Rating and Increased Price Target